Corpus overview


MeSH Disease

Human Phenotype

Overweight (1)

Obesity (1)

Anosmia (1)

Headache (1)

Cough (1)



There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Early indirect impact of COVID-19 pandemic on utilization and outcomes of reproductive, maternal, newborn, child TRANS and adolescent health services in Kenya

    Authors: DUNCAN N SHIKUKU; Irene Nyaoke; Sylvia Gichuru; Onesmus Maina; Martin Eyinda; Pamela Godia; Lucy Nyaga; Charles Ameh; Enio Garcia; Alicia Lawrynowicz; Osvaldo Uez; Irene Pagano; Anastasija Caica; Mikus Gavars; Dmitrijs Perminovs; Jelena Storozenko; Oksana Savicka; Elina Dimina; Uga Dumpis; Janis Klovins

    doi:10.1101/2020.09.09.20191247 Date: 2020-09-09 Source: medRxiv

    Background: The COVID-19 global pandemic is expected to result in 8.3-38.6% additional maternal deaths in many low-income countries. The objective of this paper was to determine the initial impact of COVID-19 pandemic on reproductive, maternal, newborn, child TRANS and adolescent health (RMNCAH) services in Kenya. Methods: Data for the first four months (March-June) of the pandemic and the equivalent period in 2019 were extracted from Kenya Health Information System. Two-sample test of proportions for hospital attendance for select RMNCAH services between the two periods were computed. Results: There were no differences in monthly mean ({+/-}SD) attendance between March-June 2019 vs 2020 for antenatal care (400,191.2{+/-}12,700.0 vs 384,697.3{+/-}20,838.6), hospital births (98,713.0{+/-}4,117.0 vs 99,634.5{+/-}3,215.5), family planning attendance (431,930.5{+/-}19,059.9 vs 448,168.3{+/-}31,559.8), post-abortion care (3,206.5{+/-}111.7 vs 448,168.3{+/-}31,559.8) and pentavalent 1 immunisation (114,701.0{+/-}3,701.1 vs 110,915.8{+/-}7,209.4), p>0.05. However, there were increasing trends for adolescent pregnancy rate, significant increases in FP utilization among young people (25.7% to 27.0%), injectable (short-term) FP method uptake (58.2% to 62.3%), caesarean section rate (14.6% to 15.8%), adolescent maternal deaths MESHD (6.2% to 10.9%) and fresh stillbirths (0.9% to 1.0%) with a reduction in implants (long-term) uptake (16.5% to 13.0%) (p<0.05). No significant change in maternal mortality ratio between the two periods (96.6 vs 105.8/100,000 live births, p=0.1023) although the trend was increasing. Conclusion: COVID-19 may have contributed to increased adolescent pregnancy, adolescent maternal death MESHD and stillbirth MESHD rates in Kenya. If this trend persists, recent gains achieved in maternal and perinatal health in Kenya will be lost. With uncertainty around the duration of the pandemic, strategies to mitigate against catastrophic indirect maternal health outcomes are urgently needed. Key words: COVID-19, maternal, reproductive, stillbirths, family planning, adolescent, mortality, Kenya.

    SARS-CoV-2 (COVID-19) infection MESHD in pregnant women: characterization of symptoms and syndromes predictive of disease and severity through real-time, remote participatory epidemiology.

    Authors: Erika Molteni; Christina M Astley; Wenjie Ma; Carole Helene Sudre; Laura A Magee; Benjamin Murray; Tove Fall; Maria F Gomez; Neli Tsereteli; Paul W Franks; John S Brownstein; Richard Davies; Jonathan Wolf; Timothy Spector; Sebastien Ourselin; Claire Steves; Andrew T Chan; Marc Modat; Xuan Ding; Chunhui Yuan; Li Peng; Wei Liu; Xiao Yi; Mengge Lyu; Guixiang Xiao; Xia Xu; Weigang Ge; Jiale He; Jun Fan; Junhua Wu; Meng Luo; Xiaona Chang; Huaxiong Pan; Xue Cai; Junjie Zhou; Jing Yu; Huanhuan Gao; Mingxing Xie; Sihua Wang; Guan Ruan; Hao Chen; Hua Su; Heng Mei; Danju Luo; Dashi Zhao; Fei Xu; Yan Li; Yi Zhu; Jiahong Xia; Yu Hu; Tiannan Guo

    doi:10.1101/2020.08.17.20161760 Date: 2020-08-19 Source: medRxiv

    Background: From the beginning of COVID-19 pandemic, pregnant women have been considered at greater risk of severe morbidity and mortality. However, data on hospitalized pregnant women show that the symptom profile and risk factors for severe disease are similar to those among women who are not pregnant, although preterm birth, Cesarean delivery, and stillbirth MESHD may be more frequent and vertical transmission TRANS is possible. Limited data are available for the cohort of pregnant women that gave rise to these hospitalized cases, hindering our ability to quantify risk of COVID-19 sequelae for pregnant women in the community. Objective: To test the hypothesis that pregnant women in community differ in their COVID-19 symptoms profile and disease severity compared to non-pregnant women. This was assessed in two community-based cohorts of women aged TRANS 18-44 years in the United Kingdom, Sweden and the United States of America. Study design: This observational study used prospectively collected longitudinal (smartphone application interface) and cross-sectional (web-based survey) data. Participants in the discovery cohort were drawn from 400,750 UK, Sweden and US women (79 pregnant who tested positive) who self-reported symptoms and events longitudinally via their smartphone, and a replication cohort drawn from 1,344,966 USA women (162 pregnant who tested positive) cross-sectional self-reports samples from the social media active user base. The study compared frequencies of symptoms and events, including self-reported SARS-CoV-2 testing and differences between pregnant and non-pregnant women who were hospitalized and those who recovered in the community. Multivariable regression was used to investigate disease severity and comorbidity effects. Results: Pregnant and non-pregnant women positive for SARS-CoV-2 infection MESHD drawn from these community cohorts were not different with respect to COVID-19-related severity. Pregnant women were more likely to have received SARS-CoV-2 testing than non-pregnant, despite reporting fewer clinical symptoms. Pre-existing lung disease MESHD was most closely associated with the severity of symptoms in pregnant hospitalized women. Heart and kidney diseases MESHD and diabetes MESHD were additional factors of increased risk. The most frequent symptoms among all non-hospitalized women were anosmia HP anosmia MESHD [63% in pregnant, 92% in non-pregnant] and headache HP headache MESHD [72%, 62%]. Cardiopulmonary symptoms, including persistent cough HP cough MESHD [80%] and chest pain HP chest pain MESHD [73%], were more frequent among pregnant women who were hospitalized. Gastrointestinal symptoms, including nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD, were different among pregnant and non-pregnant women who developed severe outcomes. Conclusions: Although pregnancy is widely considered a risk factor for SARS-CoV-2 infection MESHD and outcomes, and was associated with higher propensity for testing, the profile of symptom characteristics and severity in our community-based cohorts were comparable to those observed among non-pregnant women, except for the gastrointestinal symptoms. Consistent with observations in non-pregnant populations, comorbidities such as lung disease MESHD and diabetes MESHD were associated with an increased risk of more severe SARS-CoV-2 infection MESHD during pregnancy. Pregnant women with pre-existing conditions require careful monitoring for the evolution of their symptoms during SARS-CoV-2 infection MESHD.

    Characteristics and outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection MESHD in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS)

    Authors: Marian Knight; Kathryn Bunch; Nicola Vousden; Edward Morris; Nigel Simpson; Christopher Gale; Patrick O'Brien; Maria Quigley; Peter Brocklehurst; Jennifer J Kurinczuk

    doi:10.1101/2020.05.08.20089268 Date: 2020-05-12 Source: medRxiv

    Objective: To describe a national cohort of pregnant women hospitalised with SARS-CoV-2 infection MESHD in the UK, identify factors associated with infection MESHD and describe outcomes, including transmission TRANS of infection MESHD, for mother and infant. Design: Prospective national population-based cohort study using the UK Obstetric Surveillance System (UKOSS). Setting: All 194 obstetric units in the UK Participants: 427 pregnant women admitted to hospital with confirmed Sars-CoV-2 infection between 01/03/2020 and 14/04/2020. 694 comparison women who gave birth between 01/11/2017 and 31/10/2018. Main outcome measures: Incidence of maternal hospitalisation, infant infection MESHD. Rates of maternal death, level 3 critical care unit admission, preterm birth, stillbirth MESHD, early neonatal death MESHD, perinatal death; odds ratios for infected versus comparison women. Results: Estimated incidence of hospitalisation with confirmed SARS-CoV-2 in pregnancy 4.9 per 1000 maternities (95%CI 4.5-5.4). The median gestation at symptom onset TRANS was 34 weeks (IQR 29-38). Black or other minority ethnicity (aOR 4.49, 95%CI 3.37-6.00), older maternal age TRANS (aOR 1.35, 95%CI 1.01-1.81 comparing women aged TRANS 35+ with those aged TRANS 30-34), overweight HP and obesity HP obesity MESHD (aORs 1.91, 95%CI 1.37-2.68 and 2.20, 95%CI 1.56-3.10 respectively compared to women with a BMI<25kg/m2) and pre-existing comorbidities (aOR 1.52, 95%CI 1.12-2.06) were associated with admission with SARS-CoV-2 during pregnancy. 247 women (58%) gave birth or had a pregnancy loss; 180 (73%) gave birth at term. 40 (9%) hospitalised women required respiratory support. Twelve infants (5%) tested positive for SARS-CoV-2 RNA, six of these infants within the first 12 hours after birth. Conclusions: The majority of pregnant women hospitalised with SARS-CoV-2 were in the late second or third trimester, supporting guidance for continued social distancing measures in later pregnancy. Most had good outcomes and transmission TRANS of SARS-CoV-2 to infants was uncommon. The strong association between admission with infection MESHD and black or minority ethnicity requires urgent investigation and explanation. Study Registration: ISRCTN 40092247

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.